Log In
Print
BCIQ
Print
Print this Print this
 

Rilotumumab (AMG 102)

  Manage Alerts
Collapse Summary General Information
Company Amgen Inc.
DescriptionHuman mAb against human hepatocyte growth factor/scatter factor (HGF/SF)
Molecular Target Hepatocyte growth factor/scatter factor (HGF/SF)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase III
Standard IndicationGastric cancer
Indication DetailsTreat gastric cancer; Treat locally advanced or metastatic gastric or gastroesophageal cancer
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today